A Phase 3 interventional study of Olanzapine and Fluoxetine combination (OFC) and Fluoxetine in Treatment Resistant Depression, sponsored by Eli Lilly and Company. Completed at 66 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-04-01.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States — 43 open to participants now, 65 under way, 6 of them phase 3. Depressive Disorder, Treatment-Resistant · United States.
Among the 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States, this one is the 4th largest by enrollment of the 181 interventional ones that give a count, is one of 4 that started in 2009, is one of 18 in phase 3, and was the 18th registered.
448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →43 of the 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States are open now. Recruiting first, the newest first:
NeuroRx, Inc. · Sites in United States
Ages 18–80
Mayo Clinic · Sites in United States
Ages 22–60
Motif Neurotech, Inc. · Sites in United States
Ages 22–85
BrainHealth Solutions, Inc. · Sites in United States
Ages 65+
Mclean Hospital · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
204 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 58 · Phase 3 23 · Phase 4 17
First in 2001; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 892 is above the median of 59 across 372 interventional studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 38 across the 181 interventional studies, 83 across the 22 observational. Of the 119 that completed or were terminated, 70 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 204 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 5 studies filed under Depressive Disorder, Treatment-Resistant — fewer than ten, so there is no comparison to draw.
20 of the studies in Depressive Disorder, Treatment-Resistant with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041479Phase 3Weill Medical College of Cornell UniversityBiomarker-guided rTMS for Treatment Resistant Depression | 2027-04 |
| NCT04684706University of PennsylvaniaCompressed Intermittent Theta Burst Stimulation | 2026-11-30 |
| NCT06938841University of California, San DiegoMaintenance rTMS for Depression (Maitr-De) | 2026-11-30 |
| NCT03573349Mayo ClinicKetamine Associated ACC GABA and Glutamate Change and Depression Remission: | 2026-12 |
| NCT07310381Stanford UniversityVagus Nerve Stimulation (VNS) Electroencephalogram (EEG) Protocol Supplement | 2026-12-31 |
Add all 20 to your calendar (.ics) → With an account.
Among the 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether olanzapine and fluoxetine combination (OFC) if used for a long time (47 weeks) makes patients suffering from Treatment Resistant Depression stable, determine if OFC is safe when used to treat patients with Treatment Resistant Depression for a long time (up to 47 weeks), to determine whether olanzapine and fluoxetine combination or fluoxetine alone is better to treat Treatment Resistant Depression when treated for a long time (up to 47 weeks) and to assess the quality of life during treatment.
This is a multicenter, randomized, double-blind, active comparator-controlled, parallel study of participants with Treatment Resistant Depression (TRD), comparing the efficacy and safety of olanzapine and fluoxetine Combination (OFC) versus fluoxetine in relapse prevention of stabilized participants with TRD. The study will consist of 4 phases: a screening phase; a 6- to 8-week open-label acute treatment phase; a 10- to 12-week open-label stabilization phase; and a 27- to 29-week double-blind relapse prevention treatment phase. Participants who demonstrate response to open-label OFC during the acute treatment phase will continue into the stabilization phase. Participants who remain stable while receiving open-label OFC during this phase will be randomized to receive either OFC or fluoxetine during the double-blind relapse prevention phase. Investigators and participants will be blinded to the precise duration of the stabilization period, the definition of remission, and the criteria for entry into the relapse prevention phase; this information is described in a supplement given to Ethical Review Boards (ERBs) and regulatory authorities.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Olanzapine and Fluoxetine combination (OFC)
Drug: Fluoxetine
Drug pages: Olanzapine · Fluoxetine
Open label acute phase: introductory dose for 4 days then 3 milligram (mg) Olanzapine and 25 mg Fluoxetine Combination (3/25), 6/25, 12/25, 6/50, 12/50 or 18/50, oral, daily, for 6-8 weeks. Open label stabilization phase: 6/25, 12/25, 6/50, 12/50 or 18/50 mg, oral, daily for 16-20 weeks. Double blind relapse prevention phase: dose determined during stabilization phase at Week 17, oral, daily, for 27 weeks.
Also known as: Symbyax, LY900000
25 or 50 mg/day fixed dosing for 27 weeks
Also known as: Prozac, LY1101440
Time to Relapse by Any Criteria
Relapse defined as meeting any of these criteria: 50% increase in Montgomery-Asberg Depression Rating Scale (MADRS) score from randomization with a Clinical Global Impressions-Severity (CGI-S) of Depression score increase to a score of 4 or more; Hospitalized for depression or suicidality; Discontinued due to lack of efficacy/worsening of depression/suicidality. MADRS is a 10-item rating scale for depressive mood symptoms severity, items rated on 0-6 scale, with total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (the most extremely ill). Lack of Efficacy/Worsening of depression was at discretion of investigator based on clinical observation. Suicidality is thoughts or actions of self-harm as determined by the investigator. Those who did not relapse were "censored" at their last observation.
Time frame: Randomization (Week 20) to Week 47
Percentage of Participants Who Relapse by Any Criteria
Relapse is defined as meeting any of the following criteria: 50% increase in Montgomery-Asberg Depression Rating Scale (MADRS) score from randomization with concomitant Clinical Global Impressions-Severity (CGI-S) of Depression score increase to a score of 4 or more; Hospitalization for depression or suicidality; Discontinuation due to lack of efficacy/worsening of depression/suicidality. MADRS is a rating scale for severity of depressive mood symptoms with 10 items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (the most extremely ill). Lack of Efficacy/Worsening of depression was at the discretion of the investigator and based on clinical observation. Suicidality is thoughts or actions of self-harm as determined by the investigator.
Time frame: Randomization (Week 20) to Week 47
Percentage of Participants Who Relapse Based on Montgomery-Åsberg Depression Rating Scale (MADRS) Score With Concomitant Clinical Global Impressions-Severity (CGI-S) of Depression Score
Relapse is defined as a 50% increase in the Montgomery-Asberg Depression Rating Scale (MADRS) score from randomization with concomitant Clinical Global Impressions-Severity (CGI-S) of Depression score increase to a score of 4 or more. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (the most extremely ill).
Time frame: Randomization (Week 20) to Week 47
Percentage of Participants Who Relapse as Measured by Hospitalization for Depression or Suicidality
Time frame: Randomization (Week 20) to Week 47
Percentage of Participants Who Relapse as Measured by Discontinuation Due to Lack of Efficacy/Worsening of Depression/Suicidality
Lack of Efficacy/Worsening of depression was at the discretion of the investigator and was based on clinical observation. Suicidality is thoughts or actions of self-harm as determined by the investigator.
Time frame: Randomization (Week 20) to Week 47
Time to Relapse Based on the Montgomery-Åsberg Depression Rating Scale (MADRS) Score With Concomitant Clinical Global Impressions-Severity (CGI-S) of Depression Score
Relapse is defined as a 50% increase in the Montgomery-Asberg Depression Rating Scale (MADRS) score from randomization with concomitant Clinical Global Impressions-Severity (CGI-S) of Depression score increase to a score of 4 or more. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (the most extremely ill). Those who did not relapse were "censored" at their last observation.
Time frame: Randomization (Week 20) to Week 47
Time to Relapse as Measured by Hospitalization for Depression or Suicidality
Those who did not relapse were "censored" at their last observation.
Time frame: Randomization (Week 20) to Week 47
Time to Relapse as Measured by Discontinuation Due to Lack of Efficacy/Worsening of Depression/Suicidality
Lack of Efficacy/Worsening of depression was at the discretion of the investigator and was based on clinical observation. Suicidality is thoughts or actions of self-harm as determined by the investigator. Those who did not relapse were "censored" at their last observation.
Time frame: Randomization (Week 20) to Week 47
Percentage of Participants Responding to Treatment During Open-Label Acute Treatment Phase
A 50% or greater improvement from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) and a Clinical Global Impressions-Severity (CGI-S) of Depression score ≤3 will be considered as response criteria met. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants).
Time frame: Week 0 to Week 8
Percentage of Participants Maintaining Response at Any Point During Stabilization Treatment Phase
A 50% or greater improvement from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) and a Clinical Global Impressions-Severity (CGI-S) of Depression score ≤3 will be considered as response criteria met. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants).
Time frame: Week 8 to Week 20
Percentage of Participants Achieving Remission at Any Point During Stabilization Treatment Phase
Remission is defined as the Montgomery-Asberg Depression Rating Scale (MADRS) score ≤8. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
Time frame: Week 8 to Week 20
Percentage of Participants Maintaining Remission
Remission is defined as the Montgomery-Asberg Depression Rating Scale (MADRS) score ≤8. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
Time frame: Randomization (Week 20) to Week 47
Mean Change From Week 20 to Week 47 in Montgomery-Asberg Depression Rating Scale (MADRS) Using Mixed-Effects Model Repeated Measures (MMRM) Analysis
The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.
Time frame: Randomization (Week 20), Week 47
Mean Change From Week 20 to Week 47 in Montgomery-Asberg Depression Rating Scale (MADRS) Using Last Observation Carried Forward (LOCF) Analysis
The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) Mean values were controlled for baseline (Week 20), treatment and country.
Time frame: Randomization (Week 20), up to Week 47
Mean Change From Week 20 to Week 47 in Clinical Global Impressions - Severity (CGI-S) of Depression Using Mixed-Effects Model Repeated Measures (MMRM) Analysis
CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Least Squares (LS) Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.
Time frame: Randomization (Week 20), Week 47
Resource Utilization - Average Number of Hours Worked for Pay Per Week at Week 47
Time frame: Week 47
Resource Utilization (Number of Psychiatric Visits, Number of Emergency Room or Equivalent Facility Visits for Psychiatric Illness)
Resource utilization is defined as the average number of psychiatric visits and number of emergency room or equivalent facility visits for psychiatric illness.
Time frame: Randomization (Week 20) to Week 47
Change From Week 20 to Week 47 Endpoint in the Sheehan Disability Scale (SDS)
The SDS is completed by the participant and is used to assess the effect of the participant's symptoms on their work or school (Item 1), social (Item 2), and family life and home responsibilities (Item 3). Each item is measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. Total scores is the sum of the 3 items and range from 0 to 30 with higher values indicating greater disruption in the participant's work/social/family life. Least Squares (LS) Mean values were controlled for baseline (Week 20), treatment and country.
Time frame: Randomization (Week 20), up to Week 47
Percent of Participants With Treatment-Emergent Akathisia
Barnes Akathisia Scale (BAS) rates observable, restless movements of drug-induced akathisia as well as the subjective awareness of restlessness and any distress associated with the akathisia. It consists of 4 items. 3 items (objective akathisia, subjective awareness of restlessness and subjective distress related to restlessness) rated on a 4-point scale, with 0 being no akathisia and 3 being severe akathisia. Item 4 (global clinical assessment of Akathisia) is derived from the responses on Items 1-3 rated on a 6-point scale, with 0 being absence and 5 being extreme Akathisia. Treatment emergent akathisia is defined as a global clinical assessment score on BAS \<2 at baseline (Week 20) and a global clinical assessment score on BAS ≥2 post-baseline (Weeks 21-47).
Time frame: Randomization (Week 20) to Week 47
Percent of Participants With Treatment-Emergent Parkinsonism
Simpson-Angus Scale is used to measure Parkinsonian-type symptoms in participants exposed to neuroleptics. The scale consists of 10 items, each rated on a 5-point scale, with 0 meaning complete absence of the condition and 4 meaning the presence of the condition in extreme form. The total score is obtained by adding the items and ranges from 0-40 with higher scores indicating worse conditions. Treatment emergent parkinsonism is defined as total score ≤3 of items 1 through 10 of the Simpson-Angus scale at baseline (Week 20) and a total score \>3 of items 1 through 10 post-baseline (Weeks 21-47).
Time frame: Randomization (Week 20) to Week 47
Percent of Participants With Treatment-Emergent Dyskinesia
Abnormal Involuntary Movement Scale (AIMS) is a 12-item scale designed to record the occurrence of dyskinetic movements. Items 1 through 10 are rated on a 5-point scale, with 0 being no dyskinetic movements and 4 being severe dyskinetic movements. Items 11 and 12 are yes/no questions regarding the dental condition of the participants. Treatment emergent dyskinesia is defined as a score ≥3 on any one of the AIMS items 1-7 post-baseline (Weeks 21-47) or scores ≥2 on any two of the AIMS items 1-7 post-baseline (Weeks 21-47) among participants without either criteria at baseline (Week 20).
Time frame: Randomization (Week 20) to Week 47
Mean Change From Week 20 to Week 47 in Fasting Total Cholesterol
Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.
Time frame: Randomization (Week 20), Week 47
Percent of Participants With Treatment-Emergent High Fasting Total Cholesterol
Borderline to High fasting total cholesterol: ≥200 milligrams/deciliter (mg/dL) and \<240 mg/dL at baseline and ≥240 mg/dL any time post baseline; Normal to Borderline fasting total cholesterol: \<200 mg/dL at baseline, ≥200 mg/dL and \<240 mg/dL any time post baseline; Normal to High fasting total cholesterol: \<200 mg/dL at baseline and ≥240 mg/dL any time post baseline.
Time frame: Randomization (Week 20) to Week 47
Mean Change From Week 20 to Week 47 in Fasting Low-Density Lipoprotein (LDL) Cholesterol
Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.
Time frame: Randomization (Week 20), Week 47
Percent of Participants With Treatment-Emergent High Fasting Low-Density Lipoprotein (LDL) Cholesterol
Borderline to High fasting LDL cholesterol: ≥100 milligrams/deciliter (mg/dL) and \<160 mg/dL at baseline and ≥160 mg/dL any time post baseline; Normal to Borderline fasting LDL cholesterol: \<100 mg/dL at baseline, ≥100 mg/dL and \<160 mg/dL any time post baseline; Normal to High fasting LDL cholesterol: \<100 mg/dL at baseline and ≥160 mg/dL any time post baseline.
Time frame: Randomization (Week 20) to Week 47
Mean Change From Week 20 to Week 47 in Fasting High-Density Lipoprotein (HDL) Cholesterol
Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.
Time frame: Randomization (Week 20), Week 47
Percent of Participants With Treatment-Emergent Low Fasting High-Density Lipoprotein (HDL) Cholesterol
Normal to Low fasting HDL cholesterol is ≥40 milligrams/deciliter (mg/dL) at baseline and \<40 mg/dL anytime post baseline.
Time frame: Randomization (Week 20) to Week 47
Percent of Participants With Treatment-Emergent Hepatic Events
Participants with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<=3 times the upper limit of normal (ULN) at baseline, with ALT or AST \>=3 times the ULN post-baseline and total bilirubin \>=2 times ULN at the same time are considered having treatment-emergent hepatic events.
Time frame: Randomization (Week 20) to Week 47
Mean Change From Week 20 to Week 47 in Fasting Triglycerides
Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.
Time frame: Randomization (Week 20), Week 47
Percent of Participants With Treatment-Emergent High Fasting Triglycerides
Borderline to High fasting triglycerides: ≥150 milligrams/deciliter (mg/dL) and \<200 mg/dL at baseline and ≥200 mg/dL any time post baseline; Normal to Borderline fasting triglycerides: \<150 mg/dL at baseline, ≥150 mg/dL and \<200 mg/dL any time post baseline; Normal to High fasting triglycerides: \<150 mg/dL at baseline and ≥200 mg/dL any time post baseline.
Time frame: Randomization (Week 20) to Week 47
Mean Change From Week 20 to Week 47 in Fasting Glucose
Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.
Time frame: Randomization (Week 20), Week 47
Percent of Participants With Treatment-Emergent High Fasting Glucose
Impaired to High fasting glucose: ≥100 milligrams/deciliter (mg/dL) and \<126 mg/dL at baseline and ≥126 mg/dL any time post baseline; Normal to High glucose: \<100 mg/dL at baseline and ≥126 mg/dL any time post baseline; Normal to Impaired fasting glucose is \<100 mg/dL at baseline, ≥100 mg/dL and \<126 mg/dL any time post baseline; Normal/Impaired to High fasting glucose: \<126 mg/dL at baseline and ≥126 mg/dL any time post baseline.
Time frame: Randomization (Week 20) to Week 47
Mean Change From Week 20 to Week 47 in Weight
Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.
Time frame: Randomization (Week 20), Week 47
Percent of Participants With Week 20-to-Week 47 Endpoint Increase in Weight of at Least 7%
Time frame: Week 20 to Week 47
Percent of Participants With Suicide-Related Thoughts and Behaviors
Columbia Suicide Rating Scale (C-SSRS) captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal ideation: a "yes" answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation. Suicidal behavior: a "yes" answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide.
Time frame: Randomization (Week 20) to Week 47
Mean Change in Corrected (for Rate) Cardiac QT Interval Using Fridericia's Formula (QTcF) on Electrocardiogram
Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes baseline (Week 20), treatment, country, visit, and treatment by visit interaction.
Time frame: Randomization (Week 20), Week 47
Percent of Participants With Treatment-Emergent Corrected (for Rate) Cardiac QT Interval Using Fridericia's Formula (QTcF) on Electrocardiogram ≥500 Milliseconds (Msec)
Data presented are the percent of participants whose baseline corrected (for rate) cardiac QT interval \<500 msec with post-baseline corrected (for rate) cardiac QT interval ≥500 msec.
Time frame: Randomization (Week 20) to Week 47
Percent of Participants With a 60 Milliseconds (Msec) Increase in Fridericia-Corrected (for Rate) Cardiac QT Interval (QTcF) on Electrocardiogram
Time frame: Randomization (Week 20) to Week 47
Kaplan-Meier Estimate of Percentage of Subjects Not Relapsing at Week 27 (Day 189)
Relapse is defined as meeting any of the following criteria (Relapse-any reason): 50% increase in MADRS score from randomization with concomitant CGI-S of Depression score increase to a score of 4 or more (MADRS score/CGI-S Depression Score); Hospitalization for depression or suicidality; Discontinuation due to lack of efficacy/worsening of depression/suicidality. MADRS is a rating scale for severity of depressive mood symptoms with 10 items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (the most extremely ill). Lack of Efficacy/Worsening of depression was at the discretion of the investigator and based on clinical observation. Suicidality is thoughts or actions of self-harm as determined by the investigator.
Time frame: Randomization (Week 20) to Week 27
| Milestone | OFC (SPII ) | OFC (SPIII) | OFC (SPIV) | Flu (SPIV) |
|---|---|---|---|---|
| Started | 892 | 0 | 0 | 0 |
| Completed | 655 | 0 | 0 | 0 |
| Not completed | 237 | 0 | 0 | 0 |
| Withdrew: Response criteria not met | 80 | 0 | 0 | 0 |
| Withdrew: Adverse event | 44 | 0 | 0 | 0 |
| Withdrew: Entry criteria not met | 34 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 39 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 14 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 13 | 0 | 0 | 0 |
| Withdrew: Physician decision | 4 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 8 | 0 | 0 | 0 |
| Withdrew: Unknown, not otherwise specified | 1 | 0 | 0 | 0 |
| Milestone | OFC (SPII ) | OFC (SPIII) | OFC (SPIV) | Flu (SPIV) |
|---|---|---|---|---|
| Started | 0 | 655 | 0 | 0 |
| Completed | 0 | 444 | 0 | 0 |
| Not completed | 0 | 211 | 0 | 0 |
| Withdrew: Stabilization criteria not met | 0 | 62 | 0 | 0 |
| Withdrew: Blinded randomization criteria not met | 0 | 30 | 0 | 0 |
| Withdrew: Adverse event | 0 | 28 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 41 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 24 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 9 | 0 | 0 |
| Withdrew: Entry criteria not met | 0 | 6 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 5 | 0 | 0 |
| Withdrew: Physician decision | 0 | 4 | 0 | 0 |
| Withdrew: Relapse criteria met | 0 | 1 | 0 | 0 |
| Withdrew: Unknown, not otherwise specified | 0 | 1 | 0 | 0 |
| Milestone | OFC (SPII ) | OFC (SPIII) | OFC (SPIV) | Flu (SPIV) |
|---|---|---|---|---|
| Started | 0 | 0 | 221 | 223 |
| Completed | 0 | 0 | 139 | 117 |
| Not completed | 0 | 0 | 82 | 106 |
| Withdrew: Relapse criteria met | 0 | 0 | 24 | 63 |
| Withdrew: Adverse event | 0 | 0 | 19 | 10 |
| Withdrew: Withdrawal by subject | 0 | 0 | 16 | 15 |
| Withdrew: Protocol violation | 0 | 0 | 11 | 5 |
| Withdrew: Lost to follow-up | 0 | 0 | 3 | 8 |
| Withdrew: Sponsor decision | 0 | 0 | 5 | 4 |
| Withdrew: Entry criteria not met | 0 | 0 | 2 | 1 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 |
Relapse defined as meeting any of these criteria: 50% increase in Montgomery-Asberg Depression Rating Scale (MADRS) score from randomization with a Clinical Global Impressions-Severity (CGI-S) of Depression score increase to a score of 4 or more; Hospitalized for depression or suicidality; Discontinued due to lack of efficacy/worsening of depression/suicidality. MADRS is a 10-item rating scale for depressive mood symptoms severity, items rated on 0-6 scale, with total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (the most extremely ill). Lack of Efficacy/Worsening of depression was at discretion of investigator based on clinical observation. Suicidality is thoughts or actions of self-harm as determined by the investigator. Those who did not relapse were "censored" at their last observation.
| days | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Time to Relapse by Any Criteria | NA ± 10.0 | NA ± 5.9 |
Relapse is defined as meeting any of the following criteria: 50% increase in Montgomery-Asberg Depression Rating Scale (MADRS) score from randomization with concomitant Clinical Global Impressions-Severity (CGI-S) of Depression score increase to a score of 4 or more; Hospitalization for depression or suicidality; Discontinuation due to lack of efficacy/worsening of depression/suicidality. MADRS is a rating scale for severity of depressive mood symptoms with 10 items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (the most extremely ill). Lack of Efficacy/Worsening of depression was at the discretion of the investigator and based on clinical observation. Suicidality is thoughts or actions of self-harm as determined by the investigator.
| percentage of participants | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Percentage of Participants Who Relapse by Any Criteria | 15.8 | 31.8 |
Relapse is defined as a 50% increase in the Montgomery-Asberg Depression Rating Scale (MADRS) score from randomization with concomitant Clinical Global Impressions-Severity (CGI-S) of Depression score increase to a score of 4 or more. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (the most extremely ill).
| percentage of participants | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Percentage of Participants Who Relapse Based on Montgomery-Åsberg Depression Rating Scale (MADRS) Score With Concomitant Clinical Global Impressions-Severity (CGI-S) of Depression Score | 14.0 | 28.3 |
| percentage of participants | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Percentage of Participants Who Relapse as Measured by Hospitalization for Depression or Suicidality | 1.8 | 1.3 |
Lack of Efficacy/Worsening of depression was at the discretion of the investigator and was based on clinical observation. Suicidality is thoughts or actions of self-harm as determined by the investigator.
| percentage of participants | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Percentage of Participants Who Relapse as Measured by Discontinuation Due to Lack of Efficacy/Worsening of Depression/Suicidality | 10.9 | 28.3 |
Relapse is defined as a 50% increase in the Montgomery-Asberg Depression Rating Scale (MADRS) score from randomization with concomitant Clinical Global Impressions-Severity (CGI-S) of Depression score increase to a score of 4 or more. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (the most extremely ill). Those who did not relapse were "censored" at their last observation.
| days | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Time to Relapse Based on the Montgomery-Åsberg Depression Rating Scale (MADRS) Score With Concomitant Clinical Global Impressions-Severity (CGI-S) of Depression Score | NA ± 10.4 | NA ± 6.2 |
Those who did not relapse were "censored" at their last observation.
| days | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Time to Relapse as Measured by Hospitalization for Depression or Suicidality | NA ± 29.9 | NA ± 4.3 |
Lack of Efficacy/Worsening of depression was at the discretion of the investigator and was based on clinical observation. Suicidality is thoughts or actions of self-harm as determined by the investigator. Those who did not relapse were "censored" at their last observation.
| days | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Time to Relapse as Measured by Discontinuation Due to Lack of Efficacy/Worsening of Depression/Suicidality | NA ± 11.8 | NA ± 5.3 |
A 50% or greater improvement from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) and a Clinical Global Impressions-Severity (CGI-S) of Depression score ≤3 will be considered as response criteria met. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants).
| percentage of participants | OFC (SPII-Wk 0-8, Acute Open-label) |
|---|---|
| Percentage of Participants Responding to Treatment During Open-Label Acute Treatment Phase | 78.0 |
A 50% or greater improvement from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) and a Clinical Global Impressions-Severity (CGI-S) of Depression score ≤3 will be considered as response criteria met. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants).
| percentage of participants | OFC (SPIII) |
|---|---|
| Percentage of Participants Maintaining Response at Any Point During Stabilization Treatment Phase | 68.2 |
Remission is defined as the Montgomery-Asberg Depression Rating Scale (MADRS) score ≤8. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
| percentage of participants | OFC (SPIII) |
|---|---|
| Percentage of Participants Achieving Remission at Any Point During Stabilization Treatment Phase | 77.9 |
Remission is defined as the Montgomery-Asberg Depression Rating Scale (MADRS) score ≤8. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
| percentage of participants | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Percentage of Participants Maintaining Remission | 86.4 | 78.9 |
The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.
| units on a scale | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Mean Change From Week 20 to Week 47 in Montgomery-Asberg Depression Rating Scale (MADRS) Using Mixed-Effects Model Repeated Measures (MMRM) Analysis | 2.06 ± 0.56 | 4.97 ± 0.61 |
The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) Mean values were controlled for baseline (Week 20), treatment and country.
| units on a scale | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Mean Change From Week 20 to Week 47 in Montgomery-Asberg Depression Rating Scale (MADRS) Using Last Observation Carried Forward (LOCF) Analysis | 3.03 ± 0.71 | 6.84 ± 0.73 |
CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Least Squares (LS) Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.
| units on a scale | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Mean Change From Week 20 to Week 47 in Clinical Global Impressions - Severity (CGI-S) of Depression Using Mixed-Effects Model Repeated Measures (MMRM) Analysis | 0.20 ± 0.08 | 0.54 ± 0.08 |
| hours | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Resource Utilization - Average Number of Hours Worked for Pay Per Week at Week 47 | 37.49 ± 16.95 | 37.76 ± 14.58 |
Resource utilization is defined as the average number of psychiatric visits and number of emergency room or equivalent facility visits for psychiatric illness.
| visits per participant | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Psychiatric visits (n=136, 113) | 0.65 ± 1.43 | 0.81 ± 1.52 |
| Emergency room or equivalent facility visits | 0.00 ± 0.00 | 0.00 ± 0.00 |
The SDS is completed by the participant and is used to assess the effect of the participant's symptoms on their work or school (Item 1), social (Item 2), and family life and home responsibilities (Item 3). Each item is measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. Total scores is the sum of the 3 items and range from 0 to 30 with higher values indicating greater disruption in the participant's work/social/family life. Least Squares (LS) Mean values were controlled for baseline (Week 20), treatment and country.
| units on a scale | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Change From Week 20 to Week 47 Endpoint in the Sheehan Disability Scale (SDS) | 1.30 ± 0.72 | 3.24 ± 0.73 |
Barnes Akathisia Scale (BAS) rates observable, restless movements of drug-induced akathisia as well as the subjective awareness of restlessness and any distress associated with the akathisia. It consists of 4 items. 3 items (objective akathisia, subjective awareness of restlessness and subjective distress related to restlessness) rated on a 4-point scale, with 0 being no akathisia and 3 being severe akathisia. Item 4 (global clinical assessment of Akathisia) is derived from the responses on Items 1-3 rated on a 6-point scale, with 0 being absence and 5 being extreme Akathisia. Treatment emergent akathisia is defined as a global clinical assessment score on BAS \<2 at baseline (Week 20) and a global clinical assessment score on BAS ≥2 post-baseline (Weeks 21-47).
| percentage of participants | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Percent of Participants With Treatment-Emergent Akathisia | 0.9 | 0.9 |
Simpson-Angus Scale is used to measure Parkinsonian-type symptoms in participants exposed to neuroleptics. The scale consists of 10 items, each rated on a 5-point scale, with 0 meaning complete absence of the condition and 4 meaning the presence of the condition in extreme form. The total score is obtained by adding the items and ranges from 0-40 with higher scores indicating worse conditions. Treatment emergent parkinsonism is defined as total score ≤3 of items 1 through 10 of the Simpson-Angus scale at baseline (Week 20) and a total score \>3 of items 1 through 10 post-baseline (Weeks 21-47).
| percentage of participants | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Percent of Participants With Treatment-Emergent Parkinsonism | 1.4 | 0.0 |
Abnormal Involuntary Movement Scale (AIMS) is a 12-item scale designed to record the occurrence of dyskinetic movements. Items 1 through 10 are rated on a 5-point scale, with 0 being no dyskinetic movements and 4 being severe dyskinetic movements. Items 11 and 12 are yes/no questions regarding the dental condition of the participants. Treatment emergent dyskinesia is defined as a score ≥3 on any one of the AIMS items 1-7 post-baseline (Weeks 21-47) or scores ≥2 on any two of the AIMS items 1-7 post-baseline (Weeks 21-47) among participants without either criteria at baseline (Week 20).
| percentage of participants | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Percent of Participants With Treatment-Emergent Dyskinesia | 0.5 | 0.0 |
Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.
| milligrams/deciliter (mg/dL) | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Mean Change From Week 20 to Week 47 in Fasting Total Cholesterol | -2.65 ± 3.24 | -1.74 ± 3.52 |
Borderline to High fasting total cholesterol: ≥200 milligrams/deciliter (mg/dL) and \<240 mg/dL at baseline and ≥240 mg/dL any time post baseline; Normal to Borderline fasting total cholesterol: \<200 mg/dL at baseline, ≥200 mg/dL and \<240 mg/dL any time post baseline; Normal to High fasting total cholesterol: \<200 mg/dL at baseline and ≥240 mg/dL any time post baseline.
| percentage of participants | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Borderline to High (n= 75, 83) | 28.0 | 20.5 |
| Normal to Borderline (n=47, 59) | 17.0 | 16.9 |
| Normal to High (n=47, 59) | 2.1 | 3.4 |
Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.
| milligrams/deciliter (mg/dL) | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Mean Change From Week 20 to Week 47 in Fasting Low-Density Lipoprotein (LDL) Cholesterol | -0.72 ± 2.96 | 0.85 ± 3.20 |
Borderline to High fasting LDL cholesterol: ≥100 milligrams/deciliter (mg/dL) and \<160 mg/dL at baseline and ≥160 mg/dL any time post baseline; Normal to Borderline fasting LDL cholesterol: \<100 mg/dL at baseline, ≥100 mg/dL and \<160 mg/dL any time post baseline; Normal to High fasting LDL cholesterol: \<100 mg/dL at baseline and ≥160 mg/dL any time post baseline.
| percent of participants | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Borderline to High (n= 115, 134) | 17.4 | 10.4 |
| Normal to Borderline (n=22, 26) | 22.7 | 30.8 |
| Normal to High (n=22, 26) | 4.5 | 0.0 |
Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.
| milligrams/deciliter (mg/dL) | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Mean Change From Week 20 to Week 47 in Fasting High-Density Lipoprotein (HDL) Cholesterol | -1.71 ± 0.84 | 2.02 ± 0.92 |
Normal to Low fasting HDL cholesterol is ≥40 milligrams/deciliter (mg/dL) at baseline and \<40 mg/dL anytime post baseline.
| percentage of participants | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Percent of Participants With Treatment-Emergent Low Fasting High-Density Lipoprotein (HDL) Cholesterol | 39.2 | 25.5 |
Participants with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<=3 times the upper limit of normal (ULN) at baseline, with ALT or AST \>=3 times the ULN post-baseline and total bilirubin \>=2 times ULN at the same time are considered having treatment-emergent hepatic events.
| percentage of participants | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Percent of Participants With Treatment-Emergent Hepatic Events | 0.0 | 0.0 |
Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.
| milligrams/deciliter (mg/dL) | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Mean Change From Week 20 to Week 47 in Fasting Triglycerides | -8.24 ± 5.70 | -21.51 ± 6.20 |
Borderline to High fasting triglycerides: ≥150 milligrams/deciliter (mg/dL) and \<200 mg/dL at baseline and ≥200 mg/dL any time post baseline; Normal to Borderline fasting triglycerides: \<150 mg/dL at baseline, ≥150 mg/dL and \<200 mg/dL any time post baseline; Normal to High fasting triglycerides: \<150 mg/dL at baseline and ≥200 mg/dL any time post baseline.
| percentage of participants | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Borderline to High (n=47, 41) | 51.1 | 26.8 |
| Normal to Borderline (n= 68, 74) | 22.1 | 6.8 |
| Normal to High (n=68, 74) | 16.2 | 5.4 |
Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.
| milligrams/deciliter (mg/dL) | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Mean Change From Week 20 to Week 47 in Fasting Glucose | 3.67 ± 1.36 | -2.22 ± 1.47 |
Impaired to High fasting glucose: ≥100 milligrams/deciliter (mg/dL) and \<126 mg/dL at baseline and ≥126 mg/dL any time post baseline; Normal to High glucose: \<100 mg/dL at baseline and ≥126 mg/dL any time post baseline; Normal to Impaired fasting glucose is \<100 mg/dL at baseline, ≥100 mg/dL and \<126 mg/dL any time post baseline; Normal/Impaired to High fasting glucose: \<126 mg/dL at baseline and ≥126 mg/dL any time post baseline.
| percentage of participants | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Impaired to High (n=98, 97) | 18.4 | 7.2 |
| Normal to High (n=90, 96) | 4.4 | 5.2 |
| Normal to Impaired (n=90, 96) | 35.6 | 28.1 |
| Normal/Impaired to High (n= 188, 193) | 11.7 | 6.2 |
Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.
| kilograms (kg) | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Mean Change From Week 20 to Week 47 in Weight | 1.14 ± 0.33 | -2.78 ± 0.36 |
| percentage of participants | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Percent of Participants With Week 20-to-Week 47 Endpoint Increase in Weight of at Least 7% | 11.8 | 2.3 |
Columbia Suicide Rating Scale (C-SSRS) captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal ideation: a "yes" answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation. Suicidal behavior: a "yes" answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide.
| percentage of participants | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Suicidal Ideation | 4.1 | 6.3 |
| Suicidal Behavior | 0 | 0 |
Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes baseline (Week 20), treatment, country, visit, and treatment by visit interaction.
| milliseconds (msec) | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Mean Change in Corrected (for Rate) Cardiac QT Interval Using Fridericia's Formula (QTcF) on Electrocardiogram | -3.12 ± 1.48 | -1.55 ± 1.60 |
Data presented are the percent of participants whose baseline corrected (for rate) cardiac QT interval \<500 msec with post-baseline corrected (for rate) cardiac QT interval ≥500 msec.
| percentage of participants | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Percent of Participants With Treatment-Emergent Corrected (for Rate) Cardiac QT Interval Using Fridericia's Formula (QTcF) on Electrocardiogram ≥500 Milliseconds (Msec) | 0 | 0 |
| percentage of participants | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Percent of Participants With a 60 Milliseconds (Msec) Increase in Fridericia-Corrected (for Rate) Cardiac QT Interval (QTcF) on Electrocardiogram | 0 | 0 |
Relapse is defined as meeting any of the following criteria (Relapse-any reason): 50% increase in MADRS score from randomization with concomitant CGI-S of Depression score increase to a score of 4 or more (MADRS score/CGI-S Depression Score); Hospitalization for depression or suicidality; Discontinuation due to lack of efficacy/worsening of depression/suicidality. MADRS is a rating scale for severity of depressive mood symptoms with 10 items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (the most extremely ill). Lack of Efficacy/Worsening of depression was at the discretion of the investigator and based on clinical observation. Suicidality is thoughts or actions of self-harm as determined by the investigator.
| percentage of participants | OFC (SPIV) | Flu (SPIV) |
|---|---|---|
| Relapse-any criteria | 83.6 (77.6 to 88.1) | 66.5 (59.6 to 72.5) |
| Relapse-MADRS score/CGI-S Depression Score | 85.3 (79.3 to 89.6) | 69.6 (62.7 to 75.5) |
| Relapse-Hospitalization for depression/suicidality | 97.7 (94.0 to 99.1) | 98.6 (95.6 to 99.5) |
| Relapse-Discontinued for lack efficacy/worsening | 87.4 (81.7 to 91.4) | 69.8 (63.0 to 75.6) |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OFC (SPII) | — | 13/892 (1.5%) | 606/892 (67.9%) |
| OFC (SPIII) | — | 9/655 (1.4%) | 348/655 (53.1%) |
| OFC (SPIV) | — | 9/221 (4.1%) | 100/221 (45.2%) |
| Flu (SPIV) | — | 7/223 (3.1%) | 105/223 (47.1%) |
| Event | OFC (SPII) | OFC (SPIII) | OFC (SPIV) | Flu (SPIV) |
|---|---|---|---|---|
| DepressionPsychiatric disorders | 1/892 | 1/655 | 3/221 | 3/223 |
| CholelithiasisHepatobiliary disorders | 0/892 | 0/655 | 1/221 | 0/223 |
| CellulitisInfections and infestations | 1/892 | 1/655 | 1/221 | 0/223 |
| Metastatic neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/892 | 0/655 | 1/221 | 0/223 |
| AggressionPsychiatric disorders | 0/892 | 0/655 | 1/221 | 0/223 |
| Homicidal ideationPsychiatric disorders | 0/892 | 0/655 | 1/221 | 0/223 |
| Suicidal ideationPsychiatric disorders | 1/892 | 1/655 | 1/221 | 0/223 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/892 | 0/655 | 1/221 | 0/223 |
| Thrombophlebitis superficialVascular disorders | 0/892 | 0/655 | 1/221 | 0/223 |
| Chest painGeneral disorders | 0/892 | 0/655 | 0/221 | 1/223 |
| Event | OFC (SPII) | OFC (SPIII) | OFC (SPIV) | Flu (SPIV) |
|---|---|---|---|---|
| Weight increasedInvestigations | 151/892 | 59/655 | 8/221 | 5/223 |
| Dry mouthGastrointestinal disorders | 125/892 | 8/655 | 0/221 | 1/223 |
| Increased appetiteMetabolism and nutrition disorders | 123/892 | 11/655 | 3/221 | 1/223 |
| SomnolenceNervous system disorders | 76/892 | 20/655 | 1/221 | 3/223 |
| FatigueGeneral disorders | 68/892 | 15/655 | 2/221 | 2/223 |
| HeadacheNervous system disorders | 64/892 | 39/655 | 15/221 | 13/223 |
| InsomniaPsychiatric disorders | 20/892 | 16/655 | 8/221 | 16/223 |
| SedationNervous system disorders | 61/892 | 17/655 | 3/221 | 0/223 |
| NasopharyngitisInfections and infestations | 37/892 | 23/655 | 9/221 | 12/223 |
| DepressionPsychiatric disorders | 2/892 | 4/655 | 2/221 | 12/223 |
| Age, Continuous(years) | OFC (SPII-Wk 0-8, Acute Open-label) |
|---|---|
| Mean | 44.38 ± 11.98 |
| Sex: Female, Male(Participants) | OFC (SPII-Wk 0-8, Acute Open-label) |
|---|---|
| Female | 591 |
| Male | 301 |
| Ethnicity (NIH/OMB)(Participants) | OFC (SPII-Wk 0-8, Acute Open-label) |
|---|---|
| Hispanic or Latino | 167 |
| Not Hispanic or Latino | 725 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | OFC (SPII-Wk 0-8, Acute Open-label) |
|---|---|
| American Indian or Alaska Native | 27 |
| Asian | 115 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 101 |
| White | 634 |
| More than one race | 11 |
| Unknown or Not Reported | 3 |
| Region of Enrollment(participants) | OFC (SPII-Wk 0-8, Acute Open-label) |
|---|---|
| United States | 533 |
| Mexico | 44 |
| Puerto Rico | 20 |
| Argentina | 53 |
| Turkey | 28 |
| Russian Federation | 66 |
| South Africa | 40 |
| India | 108 |
| Body Mass Index (BMI)(kilograms/square meter (kg/m²)) | OFC (SPII-Wk 0-8, Acute Open-label) |
|---|---|
| Mean | 29.12 ± 7.36 |
The record gives a start of Aug 2009, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Olanzapine · Fluoxetine
Depressive Disorder, Treatment-Resistant →